Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

$DNLIPress releaseOct 30, 2026, 9:30 AM ETRead the release

Denali Therapeutics' AVLAYAH (tividenofusp alfa-eknm) won the 2026 Prix Galien USA 'Best Biotechnology Product' award from The Galien Foundation. AVLAYAH is the first FDA-approved biologic specifically designed to cross the blood-brain barrier, receiving accelerated approval in March 2026 for neurologic manifestations of Hunter syndrome, the first new treatment option in nearly 20 years.

Key figures

Hunter syndrome us patients: 500
Hunter syndrome worldwide patients: 2000

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.